Regeneron Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Regeneron Pharmaceuticals, Inc.
Keeping Track: Regeneron Ebola Antibody Cocktail Inmazeb Approved; Avenue Feels Pain From CRL; Scynexis Submits Oral Antifungal
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The US FDA approved the first antibody cocktail for ebolavirus infection, supporting a supply contract with BARDA. The development experience informed Regeneron's work in COVID-19.
Roche Pharma CEO Bill Anderson is excited about the prospects for REGN-COV2 but with the company and Regeneron possibly producing two million doses per year by the end of Q1 2021, meeting demand worldwide will be an impossible task.
NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Regeneron Genetics Center LLC (RGC)